

Flectronic Filing System (EFS) Data

Electronic Patent Application Submission

USPEO Use Only

EFS ID:

53936

Application ID:

10712363

Cytochrome P450 genetic

Title of Invention:

variations

First Named Inventor:

Elliott Dawson

Domestic/Foreign Application:

Domestic Application

Filing Date:

2003-11-12

Effective Receipt Date:

2004-01-19

Submission Type:

Information Disclosure

Statement

Filing Type:

Confirmation number:

1313

Attorney Docket Number:


13744-2

Total Fees Authorized:

Digital Certificate Holder: cn=David A. Farah,ou=Registered Attorneys,ou=Patent and Trademark

Office,ou=Department of Commerce,o=U.S. Government,c=US

Certificate Message Digest: 88656fd55e99d41e46609c0d1b27a9af4b8bc355



TRANSMITTAL

Electronic Version v1.1
Stylesheet Version v1.1.0

Title of Invention

Cytochrome P450 genetic variations

Application Number:

10/712363

Date:

2003-11-12

First Named Applicant:

Elliott P. Dawson

Confirmation Number: 1313
Attorney Docket Number: 13744-2

I hereby certify that the use of this system is for OFFICIAL correspondence between patent applicants or their representatives and the USPTO. Fraudulent or other use besides the filing of official correspondence by authorized parties is strictly prohibited, and subject to a fine and/or imprisonment under applicable law.

I, the undersigned, certify that I have viewed a display of document(s) being electronically submitted to the United States Patent and Trademark Office, using either the USPTO provided style sheet or software, and that this is the document(s) I intend for initiation or further prosecution of a patent application noted in the submission. This document(s) will become part of the official electronic record at the USPTO.

Submitted by:	Elec. Sign.	Sign. Capacity	
David A. Farah Registered Number: 38134	/davidfarah/	Attorney	

Documents being submitted

Files

us-ids

EfilingIDS13744-2-usidst.xml

us-ids.dtd

us-ids.xsl

Comments

It is believed that this disclosure complies with the requirements of 37 C.F.R. 1.56 and

the Manual of Patent Examining Procedures Section 707.05 (b). If for some reason the Examiner considers otherwise, it is respectfully requested that the undersigned be called so that any deficiencies can be remedied. Applicant believes that because this Disclosure Statement is being submitted within three months of the filing date and/or before the first Office Action on the merits, no fee is due. If this is incorrect, please charge any necessary fee for consideration of this Disclosure Statement to Deposit Account No. 19-2090 (Sheldon and Mak). No fee is believed due in connection with this communication. However, if it is determined that a fee is due, the Commissioner is hereby authorized to charge payment of any fees to Deposit Account No. 19-2090.





ELECTRONIS INFORMATION DISCLOSURE STATEMENT

Electronic Version v18 Stylesheet Version v18.0

> Title of Invention

Cytochrome P450 genetic variations

Application Number:

10/712363

Confirmation Number:

1313

First Named Applicant:

Elliott Dawson

Attorney Docket Number: 13744-2

Art Unit:

1637

Search string:

(6309823).pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
	1	6309823	2001-10-30	Cronin et al.	B1	435	6

Signature

Examiner Name	Date		